Serum Glucose Fluctuations Is an Independent Predictor of Adverse Outcomes in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment
Maham Laleka1, Saqib Chaudhry1, Hamza Khan1, Akif Ali1, Ashley McHugh1, Mohammad Rauf Chaudhry2, Muhammad Taimoor Khan1, Abdullah Zaki3, Laith Altaweel1, Adnan Qureshi4
1Neurology, Inova Fairfax Medical Campus, 2Neurology, Inova Loudoun Hospital, 3Neurology, DHQ teaching hospital of Gujranwala, 4Neurology
Objective:
To explore the association between serum glucose fluctuation on post treatment symptomatic intracranial hemorrhage (sICH) and mortality
Background:
 Acute hyperglycemia may increase the rate of death or disability among acute ischemic stroke patients undergoing endovascular procedures.
Design/Methods:
 We analyzed consecutive acute ischemic stroke patients who underwent endovascular treatment over 30 months at a comprehensive stroke center. Serum glucose levels within the initial 24 hours were used to calculate the mean and standard deviation (SD). Patients were grouped by the standard deviation [SD] of the mean value of serum glucose, whether above or below 25%. Outcomes included sICH, and inpatient mortality, adjusted for confounders which included age, gender, baseline NIHSS, perfusion grade (TICI) intravenous thrombolysis, history of diabetes and HBA1c.
Results:
A total of 224 patients (mean age was 68.7 years (±14.3); 44.2% were women) underwent endovascular treatment. The proportion of sICH (16.7% vs. 3.28%; p=0.0006) and inpatient mortality (18.6% vs. 7.4%; p=0.0112) were higher in patients with SD exceeding 25. After adjusting for potential confounders, serum glucose SD above 25 was significantly associated with increased rate of sICH (odds ratio [OR] 5.2; 95% confidence interval [CI] 1.5-18.5; p=0.0112) and inpatient mortality (OR 3.5; 95% CI 1.3-9.8; p=0.0154).
Conclusions:
Serum glucose fluctuations within first 24 hours maybe be therapeutic target due to its association with increased risks of sICH and inpatient mortality following endovascular treatment in acute ischemic stroke.
10.1212/WNL.0000000000205309